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xpanding the Spectrum of
rrhythmogenic Cardiomyopathy*
effrey E. Saffitz, MD, PHD, FACC
oston, Massachusetts
f the nonischemic (familial) cardiomyopathies, only ar-
hythmogenic right ventricular cardiomyopathy (ARVC)
pecifies a particular cardiac chamber in its name. This is
ot surprising in view of the striking right ventricular (RV)
nvolvement in the classical form of the disease, which is
efined by relatively specific but not highly sensitive clinical
riteria (the International Task Force criteria) (1) and/or
athological features of replacement of RV free wall myo-
ardium by fat and fibrous tissue and aneurysms of the RV
pex, posterior free wall, and outflow tract (the so-called
triangle of dysplasia”) (2). For many years after ARVC was
rst described clinically and pathologically, attention was
nderstandably focused on the RV, and it was generally held
hat the left ventricle (LV) was normal or only minimally
nvolved. In recent years, however, LV involvement has
een recognized (3) and, in some cases, the LV might be the
rimary chamber to show pathological changes classically
een in the RV form. But the most important develop-
ent in this field has been the crescendo of discovery
bout the genetic basis of ARVC (and its LV variants)
nd the recognition that most disease-causing mutations
nvolve genes encoding proteins of the desmosome (4).
See page 2175
o date, mutations have been identified in virtually all desmo-
omal proteins, including the desmosomal cadherins
desmoglein-2 and desmocollin-2) and intracellular linker
roteins of the plakin and armadillo families including
esmoplakin, plakoglobin, and plakophilin-2. And now, in
paradigm shift away from conventional clinicopathological
scertainment of disease, it is the genetics that are beginning
o drive the discovery of a far broader spectrum of disease
henotypes than originally appreciated in previous years.
In this issue of the Journal, the highly productive
nherited Cardiovascular Disease Group led by William
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From Harvard Medical School and Beth Israel Deaconess Medical Center, Boston,
assachusetts.. McKenna at the Heart Hospital in London describes the
linical-genetic profile of 42 patients with a disease entity
hey term “left-dominant arrhythmogenic cardiomyopathy”
LDAC) in a report that significantly broadens the bound-
ries of arrhythmogenic cardiomyopathy (5). They defined
DAC as showing “early and predominant LV involve-
ent” manifest clinically as inverted T waves in the lateral
nd/or inferior leads and ventricular arrhythmias of right
undle branch block morphology consistent with LV origin.
hey also included some patients with idiopathic myocar-
ial fibrosis (IMF), a poorly defined entity that apparently
ccounts for a few percent of sudden cardiac deaths and is
haracterized pathologically by interstitial fibrosis, especially
f the inferior LV wall, in the absence of coronary artery
isease or other structural abnormalities. The rationale for
ncluding IMF in the spectrum of arrhythmogenic cardio-
yopathy was both clinical and genetic—the clinical profile
f IMF seems to overlap with LDAC, and a desmoplakin
utation was identified in a family with clinical features of
RVC who had lost a first-degree relative to IMF. Many of
he LDAC patients presented with symptoms of arrhyth-
ias or chest pain but not heart failure, thus distinguishing
DAC from other nonischemic cardiomyopathies such as
ilated cardiomyopathy in which arrhythmias typically oc-
ur in the setting of ventricular dysfunction. Indeed, a
efining feature of LDAC is arrhythmogenesis “out of
roportion to the degree of ventricular dysfunction” (5).
cKenna et al. (5) also stressed that the types of ECG
ndings seen in many of their patients are often dismissed as
enign in the absence of coronary artery obstruction or LV
ystolic dysfunction.
The LDAC patients in this study either had a proven
amily history of LDAC/IMF or were selected from a larger
tudy population who were referred primarily for “difficult-
o-manage arrhythmia or challenging risk stratification
ssues” in the setting of presumed dilated cardiomyopathy,
ypertrophic cardiomyopathy, mitral prolapse, or myocar-
itis/LV noncompaction. In many cases, the original diag-
oses were ruled out, indicating that LDAC is often
nrecognized or misdiagnosed.
Genetic analysis identified disease-causing mutations in 7
f 24 families (13 of 34 individuals) with LDAC/IMF, a
pick-up” rate of 29%, which is roughly equivalent to that
eported for classical ARVC (4). Five of the 7 mutations
ccurred within the gene encoding desmoplakin, perhaps
uggesting that desmoplakin mutations are more likely than
ther desmosomal gene mutations to affect the LV. Of
ourse, additional studies will be required to validate this
otential relationship. It is clear, however, that much
emains to be discovered about the genetic basis of arrhyth-
ogenic cardiomyopathy, and it can be anticipated that
utations in genes other than those encoding desmosomal
roteins will eventually be identified. Interestingly, all 4
DAC patients who originally presented with chest pain
nd were presumed to have viral myocarditis were found to
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ence to the notion that inflammatory myocarditis in the
etting of arrhythmogenic cardiomyopathy has a genetic
ather than an infectious etiology.
Five study patients fulfilled echocardiographic criteria for
V noncompaction. Of these, 2 showed fibrofatty replace-
ent on endomyocardial biopsy and carried desmosomal
ene mutations. One had a family history of pathologically
ocumented ARVC, and another died suddenly and was
ound to have a post-mortem picture of IMF (but not LV
oncompaction). The final patient was Afro-Caribbean, a
opulation in which at least some normal individuals fulfill
riteria for noncompaction. These observations provide
dditional links between noncompaction and the spectrum
f arrhythmogenic cardiomyopathy while also emphasizing
hat current diagnostic criteria for LV noncompaction
equire further refinement.
Cardiac magnetic resonance imaging revealed segmental
ilation and/or wall motion abnormalities in the RV in a
ajority of LDAC patients. Right ventricular aneurysms
ere present in roughly one-third, and diminished RV
jection fraction was observed in roughly one-quarter of
DAC patients. This raises questions about whether some
atients had the “biventricular” form of arrhythmogenic
ardiomyopathy (defined as early and parallel involvement
f both ventricles) rather than the left-dominant form in
hich the LV is primarily affected. In any event, it is
ecoming increasingly apparent that there might be a
ontinuum of disease phenotypes in arrhythmogenic cardio-
yopathy from classical ARVC to the biventricular form to
DAC in which features of IMF and ventricular noncom-
action might also be manifest.
Increased recognition of the range of disease phenotypes
ecessitates a change in nomenclature. Under any circum-
tances, the term “dysplasia” is entirely inappropriate in
escribing the pathological changes seen in ARVC and the
iventricular and left-dominant variants. Dysplasia implies
n abnormality of proliferative growth, and the fact that
ature cardiac myocytes are post-mitotic automatically
recludes the use of this term. New insights into molecular
echanisms suggest that cardiac myocytes undergo degen-
rative changes in response to a primary myocyte disease
rocess, eventually leading to cell death and replacement by
fibrofatty type of scar tissue. Although suitable for the
K
rlassical form of disease, ARVC is obviously not appropriate
or the broader spectrum of diseases characterized by the
ommon features of arrhythmias out of proportion to
entricular dysfunction, fibrofatty replacement of myocar-
ium, noninfectious inflammatory infiltrates, and mutations
n desmosomal (and as yet undiscovered) genes regardless of
entricular predominance. As used in this commentary, the
erm “arrhythmogenic cardiomyopathy” with right-
ominant, biventricular, and left-dominant subtypes has
een applied increasingly and is appropriately focused on
he primary importance of arrhythmias as an early feature of
isease. While some might object to this term by pointing
ut that arrhythmias are a common feature of many types of
ardiomyopathies, the unusually high incidence of arrhyth-
ias in the absence of significant ventricular remodeling
nd dysfunction justifies adoption of this nomenclature.
ore detailed understanding of potential mechanistic links
etween arrhythmogenic cardiomyopathy and other entities
uch as IMF and ventricular noncompaction will require
urther analysis. Major advances can certainly be anticipated
s the genetic basis of arrhythmogenic cardiomyopathy
ecomes more completely understood.
eprint requests and correspondence: Dr. Jeffrey E. Saffitz,
epartment of Pathology, Beth Israel Deaconess Medical Center,
30 Brookline Avenue, Boston, Massachusetts 02215. E-mail:
saffitz@bidmc.harvard.edu.
EFERENCES
. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic
right ventricular dysplasia/cardiomyopathy. Task Force of the Working
Group Myocardia and Pericardial Disease of the European Society of
Cardiology and of the Scientific Council on Cardiomyopathies of the
International Society and Federation of Cardiology. Br Heart J 1994;
71:215–8.
. Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy
and sudden death in young people. N Engl J Med 1988;318:129–33.
. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic
manifestations of arrhythmogenic right ventricular cardiomyopathy/
dysplasia: a multicenter study. J Am Coll Cardiol 1997;30:1512–20.
. Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of right ventricular
cardiomyopathy. J Cardiovasc Electrophysio 2005;16:927–35.
. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhyth-
mogenic cardiomyopathy: an under-recognized clinical entity. J Am
Coll Cardiol 2008;52:2175–87.ey Words: arrhythmia y cardiomyopathy y genetics y magnetic
esonance imaging y sudden death.
